Corrigendum.

In the paper, "Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.",[1] published in Volume 58, issue 9 (1 November 2023), the authors have detected an error in the last sentence of paragraph 3.1 within their Results section (page 876) whereby the first two numbers should be transposed.The sentence should read as follows:Treatment exposure for FIL200, FIL100 and placebo in cohort 3 was 585.9, 387.8 and 2352.5 patient‐years, respectively.The authors apologise for this error. [Extracted from the article]